Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Parallel-Group Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT07066826 is registered in ClinicalTrials.gov with Wanbangde Pharmaceutical Group Co., LTD as lead sponsor.

NCT NCT07066826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07066826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Parallel-Group Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Lead sponsor
Wanbangde Pharmaceutical Group Co., LTD
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 29, 2025
Completion date
August 15, 2028
Enrollment
720 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer dementia